公开(公告)号：US20190194346A1

公开(公告)日：2019-06-27

申请号：US15778759

申请日：2016-11-24

申请人： Synthon Biopharmaceuticals B.V.

发明人： Miranda Maria Cornelia VAN DER LEE ,  Gerardus Joseph Andreas ARIAANS ,  Jan SCHOUTEN ,  Marion BLOMENROHR ,  Patrick Gerhard GROOTHUIS ,  Rudy Gerardus Elisabeth COUMANS

IPC分类号： C07K16/32 ,  A61P35/00 ,  A61K31/437 ,  A61K47/54 ,  A61K47/60 ,  A61K47/68 ,  C07K16/30

CPC分类号： C07K16/32 ,  A61K31/437 ,  A61K39/44 ,  A61K45/06 ,  A61K47/546 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  A61P35/00 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/92

摘要： The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tumours and haematological malignancies are claimed.

公开(公告)号：US09872903B2

公开(公告)日：2018-01-23

申请号：US14434102

申请日：2012-11-02

申请人： ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.

发明人： Ravindra K Pandey ,  Yihui Chen ,  Hua Bai ,  Zhenliang Chen

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K41/00 ,  C07D487/22 ,  A61K47/48 ,  A61K49/00 ,  A61K31/7072 ,  A61K31/337 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/706

CPC分类号： A61K41/0057 ,  A61K31/337 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K41/0071 ,  A61K47/545 ,  A61K47/546 ,  A61K47/549 ,  A61K49/0036 ,  C07D487/22

摘要： A targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof is provided, which improves the selectivity of photosensitizers to tumor cells, has better tolerance, can reach maximum blood concentration in 24 hours, has a bigger conjugated system, a longer absorption wavelength and an advantage in treating depth tumors; the wavelength area does not need to consume much energy of a light-output device and even LEDs can be used, which render PDT more practical and economical. The targeting thymidine kinase photosensitizer can be used for diagnosis and for treating prostatic carcinoma via the guidance of fluorescence imaging. The pharmaceutical composition uses a combination of a chemotherapeutic agent and the targeting thymidine kinase photosensitizer, which further improves the therapeutic effect of the PDT method, expands the application range for tumors and has good effects on metastatic tumors as well.

公开(公告)号：US09393306B2

公开(公告)日：2016-07-19

申请号：US14396802

申请日：2013-04-24

申请人： The Board of Regents of the University of Oklahoma

发明人： Youngjae You ,  Moses Bio ,  Abugafar Hossion ,  Gregory Nkepang

IPC分类号： A61K41/00 ,  A61K47/48 ,  A61K31/09 ,  A61K31/4745 ,  A61K49/00 ,  A61N5/06 ,  A61N5/10

CPC分类号： A61K41/0042 ,  A61K31/09 ,  A61K31/4745 ,  A61K47/546 ,  A61K49/0006 ,  A61N5/062 ,  A61N5/10 ,  A61N2005/0659 ,  A61N2005/0662

摘要： Activatable compositions that include at least one functional moiety and at least one cleavable linker directly or indirectly linked to the at least one functional moiety are disclosed. The at least one functional moiety is inactive when linked to the linker and activated upon cleavage of the linker. Methods of production and use of the activatable composition are also disclosed.

摘要翻译： 公开了包含至少一个功能部分和至少一个直接或间接连接至少一个功能部分的可切割连接物的可活化组合物。 当连接到连接体时，至少一个功能部分是无活性的，并且在切割接头时被激活。 还公开了可活化组合物的生产和使用方法。

公开(公告)号：US20130072438A1

公开(公告)日：2013-03-21

申请号：US13613736

申请日：2012-09-13

申请人： Joel S. Goldberg

发明人： Joel S. Goldberg

IPC分类号： A61K38/05 ,  A61P25/04 ,  A61K38/14 ,  C07K5/065 ,  C07K9/00

CPC分类号： C07K14/665 ,  A61K38/00 ,  A61K47/541 ,  A61K47/543 ,  A61K47/546 ,  A61K47/549

摘要： Disclosed herein are opioid peptide conjugates (for example, opioid peptide esters). In some embodiments, the disclosed conjugates include an opioid peptide consisting of two to six amino acids and a moiety conjugated to the opioid peptide by an ester bond. In some examples, the moiety is an alcohol, a sugar, a lipid, or dehydroascorbic acid. Also disclosed are methods of altering nociception including administering an effective amount of one or more disclosed opioid peptide conjugates to a subject (such as a human subject).

摘要翻译： 本文公开了阿片样物质肽缀合物（例如，阿片肽类肽）。 在一些实施方案中，所公开的缀合物包括由2至6个氨基酸组成的阿片样物质肽和通过酯键与阿片肽结合的部分。 在一些实例中，该部分是醇，糖，脂质或脱氢抗坏血酸。 还公开了改变伤害感受的方法，包括向受试者（例如人类受试者）施用有效量的一种或多种公开的阿片样物质蛋白缀合物。

公开(公告)号：US20120128590A1

公开(公告)日：2012-05-24

申请号：US13109873

申请日：2011-05-17

申请人： Paul Schlesinger ,  Neelesh Soman ,  Gregory Lanza ,  Samuel A. Wickline

发明人： Paul Schlesinger ,  Neelesh Soman ,  Gregory Lanza ,  Samuel A. Wickline

IPC分类号： A61K9/00 ,  A61K38/02 ,  A61K49/00 ,  B82Y5/00

CPC分类号： A61K9/1075 ,  A61K9/127 ,  A61K38/1767 ,  A61K47/546 ,  A61K47/62 ,  A61K47/6907 ,  A61K47/6911

摘要： Compositions which comprise emulsions of nanoparticles for delivery of membrane-integrating peptides are described. The nanoparticles comprise a liquid hydrophobic core coated with a lipid/surfactant layer which contains the membrane-integrating peptides. Methods to use such compositions are also described.

摘要翻译： 描述了包含用于递送膜整合肽的纳米颗粒的乳液的组合物。 纳米颗粒包含涂覆有含有膜整合肽的脂质/表面活性剂层的液体疏水核心。 还描述了使用这种组合物的方法。

公开(公告)号：US07943168B2

公开(公告)日：2011-05-17

申请号：US12043063

申请日：2008-03-05

申请人： Paul Schlesinger ,  Neelesh Soman ,  Gregory Lanza ,  Samuel A. Wickline

发明人： Paul Schlesinger ,  Neelesh Soman ,  Gregory Lanza ,  Samuel A. Wickline

IPC分类号： A61K9/66 ,  A61K49/00

CPC分类号： A61K9/1075 ,  A61K9/127 ,  A61K38/1767 ,  A61K47/546 ,  A61K47/62 ,  A61K47/6907 ,  A61K47/6911

摘要： Compositions which comprise emulsions of nanoparticles for delivery of membrane-integrating peptides are described. The nanoparticles comprise a liquid hydrophobic core coated with a lipid/surfactant layer which contains the membrane-integrating peptides. Methods to use such compositions are also described.

摘要翻译： 描述了包含用于递送膜整合肽的纳米颗粒的乳液的组合物。 纳米颗粒包含涂覆有含有膜整合肽的脂质/表面活性剂层的液体疏水核心。 还描述了使用这种组合物的方法。

公开(公告)号：US20090092550A1

公开(公告)日：2009-04-09

申请号：US11572102

申请日：2005-07-15

申请人： Max Crossley ,  Pall Thordarson ,  Neil Hunter ,  Benjamin Yap ,  Charles Andrew Collyer

发明人： Max Crossley ,  Pall Thordarson ,  Neil Hunter ,  Benjamin Yap ,  Charles Andrew Collyer

IPC分类号： A61K49/00 ,  C07D245/00 ,  A61K31/40

CPC分类号： C07D487/22 ,  A61K31/4178 ,  A61K47/546 ,  Y02A50/473 ,  Y02A50/481

摘要： The present invention relates generally to targeted molecular agents (TMAs) directed to a particular organism or group of organisms and uses thereof. More particularly, the present invention provides TMAs having a targeting moiety which comprises a natural or induced auxotrophic requirement of the particular organism as a vehicle for directing an agent linked to the moiety to be delivered to the target organism. The TMAs of the present invention are useful for targeting molecules such as antimicrobial agents and diagnostic agents to selected organisms.

摘要翻译： 本发明一般涉及针对特定生物体或一组生物体的靶向分子试剂（TMA）及其用途。 更具体地，本发明提供了具有靶向部分的TMA，其包含特定生物体的天然或诱导的营养缺陷型需求，作为用于引导与要递送至靶生物体的部分连接的药剂的载体。 本发明的TMA可用于将分子例如抗微生物剂和诊断剂靶向选定的生物体。

公开(公告)号：US20050148568A1

公开(公告)日：2005-07-07

申请号：US11074191

申请日：2005-03-07

申请人： Robert Hofmann

发明人： Robert Hofmann

IPC分类号： A61K31/02 ,  A61K31/045 ,  A61K31/075 ,  A61K31/12 ,  A61K31/135 ,  A61K31/405 ,  A61K31/535 ,  A61K31/555 ,  A61K47/48 ,  A61P33/02 ,  A61K31/335 ,  A61K31/409 ,  A61K31/5415

CPC分类号： A61K31/555 ,  A61K31/02 ,  A61K31/045 ,  A61K31/075 ,  A61K31/12 ,  A61K31/135 ,  A61K31/405 ,  A61K31/535 ,  A61K47/546 ,  A61K47/559 ,  A61K2300/00

摘要： Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to treat horses infected with Sarcocystis protozoal infections.

公开(公告)号：US20030100752A1

公开(公告)日：2003-05-29

申请号：US10159580

申请日：2002-05-31

发明人： Byron C. Robinson

IPC分类号： A61K049/00 ,  A61K031/655 ,  A61K031/555 ,  C07D487/22

CPC分类号： C07D487/22 ,  A61K47/546 ,  A61K49/085 ,  A61K49/10 ,  A61K49/106 ,  A61K51/0451 ,  A61K51/0485 ,  A61K51/0497

摘要： Substituted porphyrin and azaporphyrin deviations with various substitutents in the 12- and 17-positions of the porphyrin skeleton as pharmaceutical agents for use in photodynamic therapy, MRI diagnosis, and radiodiagnostics.

摘要翻译： 卟啉骨架的12位和17位的各种取代基的取代卟啉和氮杂卟啉偏差作为用于光动力学治疗，MRI诊断和放射诊断的药物。

公开(公告)号：US20190231888A1

公开(公告)日：2019-08-01

申请号：US16338992

申请日：2017-10-03

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Jonathan L. SESSLER ,  Min Hee LEE

IPC分类号： A61K47/54 ,  A61K31/65 ,  A61K9/00 ,  A61K47/69 ,  A61K45/06 ,  A61K49/08 ,  A61K49/00 ,  A61P35/04

CPC分类号： A61K47/546 ,  A61K9/0019 ,  A61K31/65 ,  A61K45/06 ,  A61K47/551 ,  A61K47/552 ,  A61K47/6911 ,  A61K49/0021 ,  A61K49/0052 ,  A61K49/085 ,  A61K49/10 ,  A61K49/101 ,  A61K49/1812 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07D487/22

摘要： The present disclosure relates to texaphyrin compounds linked with an antitumor antibiotic such as an anthcyanine antitumor antibiotic such as doxorubicin and danurubicin. The texaphyrin and the antitumor antibiotic are joined together by a group which is cleavable in vivo and results in increased activity and deliverance of the cytotoxic compound to target cells. Also provided herein are pharmaceutical compositions and methods of use thereof.